Gabapentin Tablet
Product Images NDC 68788-7774

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 68788-7774). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Gabapentin 800mg 500tab

Gabapentin Tablets 800 mg oral tablet label from Preferred Pharmaceuticals, Inc. The label states the product is generic for Neurontin and each tablet contains 800 mg gabapentin USP. It includes space for packaging size, expiration date, lot number, batch number, and insurance information. Storage instructions specify 20°C to 25°C with excursions permitted to 15°C to 30°C. The label includes warnings to keep medication out of reach of children and controlled room temperature storage. Directions for use are printed in English and Spanish on a yellow background.*

FDA Label Image

Figure 1 (Image 01)

A line graph showing mean pain score over 8 weeks comparing placebo and Gabapentin 3600 mg/day. The x-axis represents weeks from baseline to week 8, and the y-axis represents mean pain score from 0 to 10. The graph includes a 4-week dose titration period followed by a 4-week fixed dose period, with Gabapentin showing a greater reduction in pain score compared to placebo.*

FDA Label Image

Figure 2 (Image 02)

A line graph depicting mean pain scores over a 7-week period comparing placebo and two doses of gabapentin (1800 mg/day and 2400 mg/day). The graph includes a 3-week dose titration period and a 4-week fixed dose period, showing a decrease in mean pain scores for gabapentin groups compared to placebo.*

FDA Label Image

Figure 3 (Image 03)

Bar chart titled 'Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies' illustrating results from two studies. The y-axis represents the percentage of responders (0% to 100%). Study 1 compares placebo (PBO) at 12% with Gabapentin (GBP) 3600 mg at 29%. Study 2 compares placebo (14%) with Gabapentin 1800 mg (32%) and 2400 mg (34%). Statistical significance is noted with p-values <0.01 and <0.001.*

FDA Label Image

Cockcroft And Gault Equation (Image 04)

A mathematical formula depicting the calculation of creatinine clearance (ClCr) based on age, weight, serum creatinine, and a correction factor for female patients. The formula includes a multiplier of 0.85 for females to adjust the result.*

FDA Label Image

Gabapentin Structural Formula (Image 05)

Chemical structure of gabapentin, showing its cyclohexane ring connected to an amino methyl group and a carboxymethyl group, representing the molecular arrangement of the active ingredient Gabapentin.*

FDA Label Image

Figure 4. Responder Rate In Patients Receiving Gabapentin Expressed As A Difference From Placebo By Dose And Study: Adjunctive Therapy Studies In Patients ≥12 Years Of Age With Partial Seizures (Image 09)

A scatter plot showing the percentage difference on the y-axis versus daily dose in milligrams on the x-axis. Data points are grouped and labeled by three studies: Study a, Study b, and Study c, each represented by different colored squares. The graph displays data points for daily doses around 600 mg, 900 mg, 1200 mg, and 1800 mg, with percentage differences ranging from approximately 7% to 18%.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.